Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7680 in Hepatitis C
NCT02269059Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of MK-7680 in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in HCV viral load at Day 7, Number of participants experiencing an adverse event up to 21 days and 1 more. Started Dec 2014; status: completed.
02
Drugs
MK-7680
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02269059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269059.